08.03.2024 • NewsSandozOphthalmologyBiosimilars

Sandoz Acquires Ophthalmology Franchise from Coherus

In a move to expand its ophthalmic platform, Sandoz, the former generics and biosimilars arm of Swiss drugmaker Novartis, has completed the acquisition of Coherus BioSciences’ subsidiary Coherus Ophthalmology for $170 million.

The deal, which adds the biosimilar Cimerli (ranibizumab-eqrn) to Sandoz's portfolio, includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.

Sandoz and Coherus entered into the transaction agreement in January 2024.

Keren Haruvi, president Sandoz North America said: “Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines. With the addition of Cimerli to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”

Cimerli, is an anti-VEGF therapy, is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss.

© Shutterstock
© Shutterstock

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.